ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 study
0 Views
administrator
07/09/23
Reporting from ASCO 2023, Alex Herrera discusses the results from the SWOG study on nivolumab in advanced stage classic Hodgkin Lymphoma.
Abstract: LBA4 - SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), presented by Alex Herrera.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/o....ncology-news/esmo-vi
Produced by the European Society for Medical Oncology
http://www.esmo.org
-
Category
Show more
Facebook Comments
No comments found